X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
male (18) 18
index medicus (17) 17
female (16) 16
hematology (14) 14
adult (13) 13
middle aged (12) 12
aged (11) 11
chemotherapy (11) 11
oncology (11) 11
transplantation (9) 9
treatment outcome (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
clinical trials (7) 7
cancer (6) 6
leukemia, myeloid, acute - drug therapy (6) 6
lymphoma (6) 6
stem cells (6) 6
bone marrow (5) 5
brain mapping (5) 5
hematopoietic stem cells (5) 5
leukemia (5) 5
leukemia, myeloid, acute - mortality (5) 5
recurrence (5) 5
remission induction (5) 5
young adult (5) 5
acute myeloid leukemia (4) 4
analysis (4) 4
care and treatment (4) 4
cd34 antigen (4) 4
immunology (4) 4
neurosciences (4) 4
patients (4) 4
survival rate (4) 4
toxicity (4) 4
acute myelogenous leukemia (3) 3
adolescent (3) 3
age factors (3) 3
aged, 80 and over (3) 3
auditory perception - physiology (3) 3
blood (3) 3
collection (3) 3
colony-stimulating factor (3) 3
cortex (3) 3
cytarabine (3) 3
cytarabine - administration & dosage (3) 3
disease-free survival (3) 3
granulocyte colony-stimulating factor (3) 3
hematopoietic stem cell mobilization - methods (3) 3
high-dose cytarabine (3) 3
medicine (3) 3
mutation (3) 3
neuropsychological tests (3) 3
peripheral blood (3) 3
prognosis (3) 3
recommendations (3) 3
relapse (3) 3
remission (3) 3
stem cell transplantation (3) 3
stem-cell transplantation (3) 3
superior temporal sulcus (3) 3
survival (3) 3
time factors (3) 3
acoustic stimulation (2) 2
acoustic stimulation - methods (2) 2
adults (2) 2
aml (2) 2
analysis of variance (2) 2
antibodies, bispecific - administration & dosage (2) 2
antibodies, bispecific - adverse effects (2) 2
antibodies, bispecific - therapeutic use (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
apheresis (2) 2
apoptosis (2) 2
auditory-cortex (2) 2
brain - physiology (2) 2
cardiac patients (2) 2
cerebral cortex - physiology (2) 2
classification (2) 2
cohort studies (2) 2
combination (2) 2
conventional care regimens (2) 2
cyclophosphamide (2) 2
cyclophosphamide - administration & dosage (2) 2
cytarabine - therapeutic use (2) 2
daunorubicin (2) 2
daunorubicin - administration & dosage (2) 2
diagnosis (2) 2
diseases (2) 2
double-blind method (2) 2
elderly-patients (2) 2
feasibility studies (2) 2
flow cytometry (2) 2
follow-up studies (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Journal Article
Science, ISSN 0036-8075, 8/2008, Volume 321, Issue 5891, pp. 974 - 977
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 25, pp. 3110 - 3118
Journal Article
Journal Article
Nature, ISSN 0028-0836, 10/2004, Volume 431, Issue 7010, pp. 757 - 757
Humans have a unique ability to learn more than one language - a skill that is thought to be mediated by functional (rather than structural) plastic changes in... 
Age Factors | Brain - anatomy & histology | Humans | United Kingdom | Educational Status | Brain - physiology | Neuropsychological Tests | Learning - physiology | Reading | Neuronal Plasticity - physiology | Aging - physiology | Language | Time Factors | Parietal Lobe - anatomy & histology | Linguistics | Writing | Italy | Parietal Lobe - physiology | Speech | Principal Component Analysis
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 01/2019, Volume 54, Issue 1, pp. 123 - 129
Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin’s lymphoma patients eligible for... 
CD34 antigen | Autografts | Costs | Cytokines | Apheresis | Stem cell transplantation | Transplantation | Preempting | Patients | Lymphoma | Hematopoietic stem cells | Chemotherapy | Stem cells | Peripheral blood | Lymphomas | Cost analysis
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 03/2019, Volume 60, Issue 4, pp. 1014 - 1022
Acute myeloid leukemia (AML) is characterized by a high failure rate to achieve complete remission as well as high relapse rates that cause an emergent need... 
FLAG-Ida | anthracycline | salvage therapy | Acute myeloid leukemia | IDA REGIMEN | ADULT PATIENTS | POOR-RISK | PHASE-II | HIGH-DOSE CYTARABINE | G-CSF FLAG | FLUDARABINE | ONCOLOGY | RECOMMENDATIONS | ARA-C | HEMATOLOGY | PLUS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2019, Volume 185, Issue 3, pp. 595 - 598
Table S3. Adverse events of all grades occurring in a[yen]20% of all treated patients. 
stem cells | vismodegib | leukaemia | Hedgehog signalling | MALIGNANCIES | HEMATOLOGY | Clinical trials | Stem cells | Vismodegib | Refractory materials | Leukemia
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 10, pp. 1104 - 1111
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 03/2018, Volume 53, Issue 3, pp. 246 - 254
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. The goal of... 
CD34 antigen | Apheresis | Transplantation | Lymphoma | Patients | Hematopoietic stem cells | Infusion | Chemotherapy | Granulocyte colony-stimulating factor | Peripheral blood | Stem cells | Colony-stimulating factor | Leukocytes (granulocytic)
Journal Article
Acta Haematologica, ISSN 0001-5792, 10/2019, pp. 1 - 8
Journal Article
BONE MARROW TRANSPLANTATION, ISSN 0268-3369, 01/2019, Volume 54, Issue 1, pp. 123 - 129
Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin's lymphoma patients eligible for... 
MULTIPLE-MYELOMA | POOR MOBILIZATION | COLLECTION | ALGORITHM | RISK | IMMUNOLOGY | STEM-CELL MOBILIZATION | CHEMOTHERAPY | TRANSPLANTATION | STRATEGIES | ONCOLOGY | HEMATOLOGY | BLOOD
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e52695 - e52695
Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in... 
CONVENTIONAL CARE REGIMENS | PROGNOSTIC IMPACT | IDH2 MUTATIONS | 5-AZACYTIDINE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | TET2 | RISK MYELODYSPLASTIC SYNDROMES | DNMT3A MUTATIONS | INDUCTION | CHRONIC MYELOMONOCYTIC LEUKEMIA | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Consolidation Chemotherapy | Cytarabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - toxicity | Feasibility Studies | Leukemia, Myeloid, Acute - mortality | Maximum Tolerated Dose | Pilot Projects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Daunorubicin - administration & dosage | Azacitidine - administration & dosage | Anthracyclines | Chemotherapy | Analysis | Oncology, Experimental | Clinical trials | Aged patients | Research | Standards | Cancer | Toxicity | Leukemia | Brain cancer | Oncology | Cardiovascular disease | Kinases | Randomization | Cytarabine | Daunorubicin | Consolidation | Safety engineering | DNA methylation | Bone marrow | Remission | Heart diseases | Drug dosages | Deoxyribonucleic acid--DNA | Medical research | Hematology | Myeloid leukemia | Feasibility studies | Patients | Survival | Constraining | White blood cells | Medicine | Medical prognosis | Mutation | Acute myeloid leukemia | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
European Journal of Haematology, ISSN 0902-4441, 07/2017, Volume 99, Issue 1, pp. 42 - 50
Journal Article